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That adult humans possess active brown adipose tissue potentially leads to a paradigm shift in the under-
standing of human metabolism and of obesity. Adaptive adrenergic thermogenesis in humans represents
brown adipose tissue activity, the absence of which may contribute to middle-age obesity.During the first decade of this century, a realization has succes-
sively developed that a significant number of adult humans
possess active brown adipose tissue (Nedergaard et al., 2007;
Saito et al., 2009; van Marken Lichtenbelt et al., 2009; Virtanen
et al., 2009; Zingaretti et al., 2009). This was originally based
on observations in cancer patients examined for the presence
of metastases by positron emission tomography (PET) scanning
(examining the uptake of 18F-fluoro-2-deoxyglucose) (Neder-
gaard et al., 2007; Cypess et al., 2009). In its extrapolation, this
realization may have widespread consequences for our under-
standing of human metabolism and metabolic pathophysi-
ology—and thus on the development of therapeutic tools and
the analysis of their effects.
Thus, until now, the accumulated data concerning brown
adipose tissue function and metabolic significance obtained
from studies of rodents (Cannon and Nedergaard, 2004) have
been considered to be of scientific interest—but still somewhat
esoteric, since these data were assumed to be without direct
relevance for human physiology and pathophysiology. However,
we are now in a new metabolic world where these data can
indeed be extrapolated to the human situation, yielding new
explanations for humanmetabolic phenomena and new avenues
for therapeutic intervention. The activity of brown adipose
tissue—and particularly the absence of activity in certain
subjects—needs now to be forwarded in the discussion of
several metabolic phenomena and problems—and of solutions
for these. Our intention here is to point to some of these issues.
Implications for General Studies of Metabolism
The presence of brown adipose tissue in adult humans, and the
fact that its activity is acutely stimulated by cold (Nedergaard
et al., 2007; Saito et al., 2009), reinitiates discussions of our
ability to exhibit and develop classical nonshivering thermogen-
esis (NST), i.e., an ability to increase—with time in chronic cold—
brown fat-derived heat production and thus to cease shivering
(which is our acute and immediate heat-producing mechanism).
In a circular argument, it has been maintained that we cannot
develop NST because we do not have brown adipose tissue.
There is now at least one indication (Saito et al., 2009) that
human subjects in winter may have more brown adipose tissue
than the same subjects during summer, implying a recruitment
of NST. The mechanism behind this is not evident, as in human268 Cell Metabolism 11, April 7, 2010 ª2010 Elsevier Inc.civilization, exposure to cold in the winter is normally not much
higher than in the summer, due to clothes and house heating.
Whereas the feeling of being thermally comfortable in relatively
cool surroundings is evidently positive, alterations in the ability
to recruit NST have not normally been considered an important
factor in human physiology.
Searching for Thermogenic Alternatives May Be
Unnecessary
In retrospect, it becomes evident that significant scientific efforts
have been based on the (implicit) hypothesis that ‘‘as brown
adipose tissue is not found in adult humans, there must be alter-
native (human) mechanisms for (adaptive) thermogenesis (most
likely located in muscle).’’ A scientific goal has therefore been to
identify such alternative mechanisms. It is the conclusion of
rodent experiments that all adaptive adrenergic thermogenesis
originates in brown adipose tissue (Golozoubova et al., 2006;
Feldmann et al., 2009). The consequence of the presence of
brown adipose tissue in adult humans should therefore be that
any observable adaptive adrenergic thermogenesis should be
solely ascribed to brown adipose tissue activity. This does not
mean that futile cycles, different ion leaks, etc. do not exist and
are not thermogenic, but that there are no indications that these
mechanisms can be recruited for enhanced (adrenergic) thermo-
genesis underphysiological conditions. Inbroader terms,wealso
consider it unlikely that humans should have evolved specific
adrenergic thermogenic mechanisms not observable in rodents.
The Role of ‘‘Brite’’ Adipose Tissue
Within classical white adipose tissue depots, a particular type of
adipocytes sometimes occur. These ‘‘brite’’ (brown-in-white)
adipocytes manifest several classical brown adipocyte charac-
teristics, most notably the presence of UCP1. There is, however,
reason to believe that these cells do not represent brown adipo-
cytes of the same lineage as those found in classical brown
adipose tissue depots (Himms-Hagen, 2000), since the brite
adipocytes do not express the novel molecular markers charac-
teristic of classical brown adipocytes (Petrovic et al., 2010).
Based mainly on the contention that adult humans do not
possess brown adipose tissue, techniques to promote the
growth of these brite adipocytes have been directly or indirectly
advocated as a means to counteract obesity. To date, there
have been no quantitative investigations, even in mice, of the
relative contribution of these brite depots to total adrenergic
Figure 1. Regulation of the Activity and Recruitment of Brown
Adipose Tissue
In the resting state, the protonophoric activity of UCP1 in the mitochondrial
inner membrane is inhibited by cytosolic purine nucleotides, notably ATP.
When brown adipose tissue is activated from centers in the brain affected
by environmental temperature or acute food intake (or body energy stores),
norepinephrine (NE) is released from the sympathetic nerves innervating the
tissue. In the mature brown adipocytes, this leads to hydrolysis of the triglyc-
erides stored in the lipid droplets, and the released fatty acids (FFA) in some
way activate UCP1, overcoming the inhibition. Due to the uncoupling activity
of UCP1, the combustion of different substrates may now proceed: fatty acids
released from triglycerides (fat droplets) in the tissue are initially the main
source, but successively the main substrates for heat production are delivered
from the circulation. NE induces release of lipoprotein lipase (LPL) that
degrades chylomicrons and VLDL in the circulation, and the released fatty
acids are combusted, and there is also stimulated glucose uptake into the cells
(making active brown adipose tissue visible in fluorodeoxyglucose PET scan-
ning). The combustion of all these substrates demands high oxygen uptake,
and the blood leaving the tissue is heated but extremely oxygen depleted.
During chronic stimulation, NE also stimulates the progenitor cells in the tissue
to proliferate and the brown preadipocytes to differentiate (a process that can
also be stimulated by PPARg ligands). NE has also an antiapoptotic effect on
the cells. Thus, chronic stimulation will increase the total capacity of the tissue,
a process referred to as recruitment.
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adipose tissue depots has not been compared to that in the clas-
sical brown adipose tissue depots). In humans, in PET scans,
classical white adipose tissue depots are not visible as areas
demonstrating glucose uptake under conditions in which brown
adipose tissue is activated and visible. Thus, these brite depots
may not be of major thermogenic significance in humans, but
alternatively, their invisibility may be due to a brite adipocyte-
specific lack of thermogenic glucose uptake or limitations in
the level at which they can be detected. What the brite adipo-
cytes represent physiologically is difficult to say. Their occur-
rence is definitely of molecular and developmental interest, but
therapeutically it would now rather seem to be of interest to
promote the persistence of the genuine brown adipose tissue
depots in adult humans.
The Basic Problem of Brown Fat Activation
In some discussions in the field, it appears that UCP1 is
presumed to be innately active within the (brown fat) cells (i.e.,
it should be sufficient to increase the total amount of UCP1 in
order to enhance thermogenesis). This is not so. Although in iso-
lated mitochondria UCP1 is uninhibited and therefore spontane-
ously active, in intact cells UCP1 is constantly inhibited by purine
nucleotides in the cytosol (mainly ATP; experimentally GDP is
routinely used as an inhibitor, but this is only for practical
reasons) (Figure 1) (Cannon and Nedergaard, 2004). This inhibi-
tion has thus to be overcome through a process that probably
involves fatty acids interacting directly with UCP1 and which is
initiated physiologically by norepinephrine. Therefore, (pharma-
ceutical) projects based solely on increasing the total amount
of brown adipose tissue or UCP1 in the body may be basically
flawed—because the extra UCP1 will not automatically be
active. There are indeed no indications that the amount of
UCP1 influences basal brown adipocyte metabolic rate or total
body metabolic rate—metabolism is only influenced when
UCP1 is physiologically or pharmacologically activated. Rodents
adapted to the cold (probably also humans) develop large
amounts of brown adipose tissue—but immediately (i.e., within
seconds) after they are transferred to warmer conditions, brown
adipose tissue activity is turned off. Thus, the animal decides
continuously how much of its total thermogenic activity it needs
to compensate for heat loss, as a specific quantity (watts) and
not as a percentage of capacity available. Similarly, we must
assume that centers in the brain also determine how much of
the capacity of the tissue that is required during metaboloregu-
latory thermogenesis, i.e., the total amount of combustion
(watts) needed to adequately balance food energy intake (or
body energy content), and that this is independent of the total
amount of UCP1 and thus the capacity for thermogenesis.
Thus, any pharmaceutical goal to increase the total amount of
brown adipose tissue in the body must also encompass
a method to ensure that the tissue is adequately stimulated, in
reality by providing an adrenergic stimulation of the tissue. In
reality the necessity for acute stimulation of activation is advan-
tageous as we—if UCP1 were innately active within the brown
adipocytes—would pharmaceutically create a tissue that in an
uncontrolled way would drain our energy (cf. dinitrophenol).
A Bimodal Distribution of Brown Adipose Tissue
From observations on the occurrence of UCP1-positive cells in
the neck region, a bimodal distribution of such cells was noted:a given subject would seem to either have or not have such cells
(Zingaretti et al., 2009). Similarly, evaluations of total glucose
uptake by PET techniques indicate a bimodal distribution
between different individuals, provided that a broad span of
age groups are investigated (Saito et al., 2009); among younger
individuals, nearly everyone seems to possess brown adipose
tissue (van Marken Lichtenbelt et al., 2009). Even among individ-
uals possessing brown adipose tissue, the range of total glucose
uptake (activity) is very large (nearly two orders of magnitude);
taken together, this means that a significant contribution of
brown adipose tissue to metabolism is expected in certain
individuals and not in others. This may be an explanation forCell Metabolism 11, April 7, 2010 ª2010 Elsevier Inc. 269
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pharmaceutical treatments and experimental tests. It is foresee-
able that future metabolic studies should include a prior estimate
of an individual’s total brown adipose tissue. Unfortunately, there
are presently no simple and sufficiently sensitive methods avail-
able to determine this, other than the rather expensive PET
method, which also involves administration of relatively high
doses of radioactivity into healthy subjects.
Implications for Understanding the Etiology of Obesity
Cause or Effect
All studies to date agree that the absence of brown adipose
tissue is correlated with obesity also in humans. Although this
is only a correlation, it is reasonable today to extrapolate from
mouse data to humans. Broadly speaking, since the absence
of UCP1 activity is sufficient to cause or aggrevate obesity in
mice (Feldmann et al., 2009), the absence of brown adipose
tissue activity can be an explanation for at least a subset of
human obesities. Particularly what can be termed ‘‘age-induced
obesity’’—the general tendency of humans in middle age to
show an increasing propensity to develop obesity—is reason-
able to discuss in the context of being caused or advanced by
diminished brown adipose tissue activity.
Enough for Making an Obese Difference
It can be estimated fromPET scans that notmuchbrown adipose
tissue is found in adult humans (some tensof grams). Itmay there-
fore be questioned as to whether it could have any metabolic
significance. However, the very marked effects of UCP1 ablation
onbodycompositionofmice living at thermoneutrality (Feldmann
et al., 2009) indicate that even minor amounts of brown adipose
tissue can substantially affect metabolism. Evidently, even small
but consistent imbalances in the energy input/output equation
ultimately lead to obesity/leanness. It is clear from the mouse
experiments that the organism does not always compensate
for an absence of brown adipose tissue activity by undereating,
particularly when challenged with a palatable diet.
An Only Apparent Conundrum
It may initially seem contradictory that increasing fat accumula-
tion is associated with more UCP1/brown adipose tissue—while
claiming that an absence of UCP1 leads to obesity. However, it is
a necessary consequence of the concept of diet-induced ther-
mogenesis that the more a (healthy) organism inclines toward
obesity, the more brown adipose tissue it will develop in an
attempt to counteract the developing obesity. This will act to
reduce (but will be unable to fully prevent) the development of
obesity. In a situation where brown adipose tissue for some
reason has been lost, this counteraction can no longer function,
and thus an absence of UCP1/brown adipose tissuewill promote
a more severe obesity.
A Hypothesis Linking Aging, Obesity, and Brown
Adipose Tissue
The involution (‘‘atrophy’’) of brown adipose tissue with age,
earlier thought to occur and be completed already during early
childhood in man, was at that time suggested to result from
the increase in body size occurring with age. The subsequent
decrease in surface/volume ratio would lead to a decreased
requirement for brown adipose tissue heat production for main-
tenance of body temperature. While the high heat loss may
adequately explain the presence of brown adipose tissue in270 Cell Metabolism 11, April 7, 2010 ª2010 Elsevier Inc.children, its presence in young adults cannot be explained in
this way, nor can its involution with increasing age. Rather,
the involution would seem to be an endogenously controlled
process, which may result in an increased propensity for obesity
with age. Principally, this involution is also seen in experimental
animals with increasing age. This implies that an (endocrine)
switch takes place during late adult age, diminishing the amount
and activity of brown adipose tissue. One possible scenario for
this is discussed here.
There are studies implying a negative effect of glucocorticoids
on brown adipose tissue (Soumano et al., 2000), but little is
known about the underlying molecular mechanisms. Inactive
brown adipocytes become lipid filled and enlarged. It is in this
context of interest that the adipose depots—particularly the
supraclavicular depot—that contain islands of brown adipose
tissue in younger and slimmer human subjects are those that
enlarge, with lipid-filled white adipocyte(-like) cells, in Cushing’s
syndrome (Nieman and Ilias, 2005), supporting the existence of
an inactivating effect of the glucocorticoid system on brown
adipose tissue, even in adult humans.
In contrast, there is some evidence that sex hormones, both
androgens (Yanase et al., 2008) and estrogens (Rodriguez-
Cuenca et al., 2007), may be beneficial for brown adipocyte
differentiation. Thus, a scenario can be envisaged where in
younger years a general negative effect of glucocorticoids on
brown adipose tissue may be opposed by positive effects of
sex hormones (Figure 2). However, as sex hormone levels
diminish with increasing age, the negative effect of the glucocor-
ticoids will dominate, and a state will develop where brown
adipose tissue will atrophy, despite glucocorticoid levels being
normal. This will inhibit brown adipose tissue activity and ulti-
mately lead to its total involution. As a result, these subjects
will be in a metabolic state with an increased propensity to
develop obesity. Accordingly, the metabolic syndrome is
typically a syndrome appearing in late middle age. It may be
wondered why aging ‘‘should’’ necessitate these conse-
quences—but we have no satisfactory explanations for the
necessity of any aging process.
Implications for the Experimental Study of Obesity
Why Are Obesity Experiments Performed with Young
Cold-Exposed Mice?
Obesity is classically a problem of middle age. It is therefore
remarkable that nearly all experimental investigations into
obesity use young male mice. Further, these mice are housed
at a temperature where their metabolism is not endogenously
determined but is governed to a large extent by the need to
compensate for heat loss in order to defend body temperature.
At normal housing temperatures, mice have to constantly
increase their metabolism 50%–100% above basal metabolic
rate, a very remarkable metabolic task if transposed to humans.
Furthermore, this means that the mice at such normal animal
house temperatures are constantly subject to an increased
sympathetic drive. Most importantly, however, it is only at ther-
moneutral temperatures that it is possible to identify thermogen-
esis that is truly metaboloregulatory; at all lower temperatures,
thermoregulatory thermogenesis is activated, masking and
thus making it impossible to observe the metaboloregulatory
thermogenesis. Only at thermoneutrality can the essentiality of
Figure 2. A Hypothesis for Age-Related Brown Adipose Tissue Involution
In the young adult, the function of brown adipose tissue (BAT) is influenced, directly or indirectly, both by sex hormones (that have been reported to promote
brown adipose tissue function) and by cortisol (that inhibits brown adipose tissue function). Of the total energy intake, a certain fraction is combusted in brown
adipose tissue while the major fraction is used for organismal ‘‘work’’: basal metabolism and physical work on the surroundings, and very little is stored in
white adipose tissue (WAT). With age, the effects of the sex hormones weaken, and the inhibitory effect of cortisol is therefore relatively increased, diminishing
brown adipose tissue function. Provided that energy intake and ‘‘work’’ are unchanged, this would successively lead to obesity (increased white adipose tissue).
In conditions in which the amount of cortisol increases (e.g., stress or Cushing’s syndrome), the relative influence of cortisol of course also increases, with the
same final result: involution of brown adipose tissue and the development of obesity.
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lished, and only at this temperature can the obesity-inducing
effect of the absence of brown adipose tissue be observed.
It is to be expected that new genes influencing metabolism
and thus obesity can be identified if mice are examined under
thermoneutral conditions, since the effects of gene ablations
may have previously been overshadowed by the requirements
for thermoregulatory thermogenesis necessary at ‘‘normal’’ envi-
ronmental temperatures. Furthermore, at environmental temper-
atures below thermoneutrality, gene knockouts that increase
heat loss will result in a false impression of giving metabolic
protection against obesity. This is particularly relevant for muta-
tions that influence skin and fur quality.
Implications for the Treatment of Obesity
Thermogenesis Is Not Compensated
Based on the general adipostat/lipostat hypothesis for body
weight control, any increase in energy output should be com-
pensated by increased food intake, a process proposed to be
mainly mediated via leptin. However, as discussed in more detail
elsewhere (Cannon and Nedergaard, 2009), thermogenesis
challenges the adipostat hypothesis of body weight control:
increased thermogenesis often does not lead to a fully compen-
satory increase in food intake. Thus, activation of brown fat-
derived thermogenesis would lead to weight reduction even
without (conscious) attempts not to compensate increased
energy expenditure with increased food intake.
Two Ways to Recruit Brown Adipose Tissue
The classical physiological method to recruit brown adipose
tissue is through persistent adrenergic stimulation. This will
simultaneously also activate the thermogenic effect. Administra-
tion of synthetic PPARg ligands (thiazolidinediones) has also a
recruiting effect. However, the increased amounts of brown
adipose tissue/UCP1 are not sufficient per se to obtain a thermo-
genic effect; a means to constantly activate the UCP1 is also
needed (Sell et al., 2004). The physiological relevance of this
nonthermogenic recruitment process is not presently known—
but it may correspond to intrauterine prebirth recruitment or
prehibernation recruitment.Perhaps Only b1-Adrenoceptor-Induced Thermogenesis
in Humans
In rodents, adrenergic stimulation of thermogenesis can be
elicited (and probably physiologically is elicited) via the rather
adipose-selective b3-adrenergic receptor. If the same were
true in humans, this would be therapeutically advantageous,
as targeted b3-agonists could be used. However, brown fat
activation in humans can be inhibited by the b-adrenergic antag-
onist propranolol, given at doses normally used to inhibit
b1-adrenoceptors (Nedergaard et al., 2007). Since propranolol
is a much weaker antagonist on b3- than on b1-adrenoceptors,
the implication is that brown adipose tissue thermogenesis in
humans is primarily regulated through b1-adrenoceptors, even
though b3-adrenoceptors are present in the tissue. There is
thus reason to think that a significant difference in b-adrenergic
response between mice and humans may be encountered,
making the maintenance of a chronic activated state far from
trivial.
It may be added that even if b3 treatment were able to activate
thermogenesis in adult humans, this would probably only be in
pre-existing mature brown adipocytes. Brown preadipocytes
only possess b1-adrenergic receptors (for stimulation of prolifer-
ation), and chronic treatment with b3-agonists would therefore
not lead to a recruitment of the precursor cells found in the brown
adipose tissue depots.
Leptin
Only in very rare cases has leptin treatment provided direct
beneficial effects on obesity. A more promising avenue has
been to treat subjects undergoing weight reduction with leptin.
This is because food restriction leads to an energetic compensa-
tion through reduction of metabolism, enhancing the difficulties
of achieving weight reduction. Leptin prevents this decrease in
metabolism by stimulating thermogenesis. The site of the ther-
mogenic effect of leptin under these conditions is generally
unspecified, and an effect on muscle has often been implied.
At least in mice, the thermogenic effect of leptin treatment is
entirely mediated by brown fat (Commins et al., 2001), implying
that only subjects already possessing brown adipose tissue
would be suitable targets for this treatment (although in theCell Metabolism 11, April 7, 2010 ª2010 Elsevier Inc. 271
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adipose tissue recruitment).
Implications for Diabetes
As brown adipose tissue is an adipose tissue in the sense that its
cells accumulate lipid, the general concept has been that brown
adipose tissue produces heat by combusting this stored lipid.
However, the stores are limited, and it has thus been recognized
that lipids required for combustion are also obtained from the
rest of the organism, particularly from chylomicrons in the circu-
lation, through the activity of lipoprotein lipase. Additionally,
brown fat mitochondria are equally well suited to carbohydrate
combustion as to lipid combustion (Figure 1). The realization
that brown adipose tissue and muscle share a common origin
(Kajimura et al., 2010) may make it easier to accept the concept
that brown adipose tissue is not a selective lipid consumer but
will also readily combust carbohydrate (indeed it is glucose
uptake that is seen in the PET scans).
In an extension of this, because of its inordinately high meta-
bolic capacity, involution or inactivity of brown adipose tissue
could be a significant component in an increasing inability of
the body to dispose of glucose. Insulin stimulates glucose
uptake in brown adipocytes through mechanisms similar to
those in other insulin-sensitive tissues. However, additionally,
in brown adipocytes (as in myocytes) glucose uptake is stimu-
lated by norepinephrine. Thus, the glucose-utilizing activity of
brown adipose tissue could delay the development of a situation
in which steadily increased glucose levels would successively
lead to insulin resistance.
Since we are at rest (i.e., have no muscle glucose utilization
due to activity) during at least one-third of our lives, glucose dis-
posal mediated by brown adipose tissue may be a significant
factor in maintaining euglycemia. Additionally, one study, so far
not further explored, indicates that a specific inability of brown
adipocytes to respond to insulin stimulation can apparently lead
to a systemic glucose intolerance syndrome (Guerra et al., 2001).
A New View on the Major Goal for Therapeutic Efforts
Until now, the implicit goal for brown fat-based obesity therapies
has been to increase the amount of brown adipose tissue (or at
least UCP1) in already obese subjects—so that their excess
energy reserves could be endogenously combusted. However,
our new insights into the physiology of human brown adipose
tissue could lead to an alteration in our goals. With the under-
standing that practically all humans at a young adult age possess
active brown adipose tissue and that most humans lose the
tissue with age, a major therapeutic interest could perhaps lie
in obtaining a means to keep the tissue recruited and to avoid
its involution, and to ascertain that the tissue that is present is
being adequately activated, thus reducing obesity development.
Individuals identified as having declining brown adipose tissue
activity would be the target group. An understanding of the
processes that keep the brown adipocyte precursors in prolifer-
atively competent states capable of differentiation and that272 Cell Metabolism 11, April 7, 2010 ª2010 Elsevier Inc.inhibit the apoptosis/cell death responsible for involution of the
tissue would become the basis for new targets for therapeutic
intervention.
ACKNOWLEDGMENTS
The authors regret that space limitations have restricted the reference list such
that adequate referencing cannot be fulfilled. The authors are grateful to
members of the laboratory for discussions and to the Swedish Research
Council for continuous support of their research.
REFERENCES
Cannon, B., and Nedergaard, J. (2004). Physiol. Rev. 84, 277–359.
Cannon, B., and Nedergaard, J. (2009). Proc. Nutr. Soc. 64, 401–407.
Commins, S.P., Watson, P.M., Frampton, I.C., and Gettys, T.W. (2001). Am. J.
Physiol. 280, E372–E373.
Cypess, A.M., Lehman, S., Williams, G., Tal, I., Rodman, D., Goldfine, A.B.,
Kuo, F.C., Palmer, E.L., Tseng, Y.H., Doria, A., et al. (2009). N. Engl. J. Med.
360, 1509–1517.
Feldmann, H.M., Golozoubova, V., Cannon, B., and Nedergaard, J. (2009). Cell
Metab. 9, 203–209.
Golozoubova, V., Cannon, B., and Nedergaard, J. (2006). Am. J. Physiol. 291,
E350–E357.
Guerra, C., Navarro, P., Valverde, A.M., Arribas, M., Bruning, J., Kozak, L.P.,
Kahn, C.R., and Benito, M. (2001). J. Clin. Invest. 108, 1205–1213.
Himms-Hagen, J. (2000). In The b3-Adrenoreceptor, A.D. Strosberg, ed. (Lon-
don: Taylor and Francis), pp. 97–119.
Kajimura, S., Seale, P., and Spiegelman, B. (2010). Cell Metab., in press.
Nedergaard, J., Bengtsson, T., and Cannon, B. (2007). Am. J. Physiol. 293,
E444–E452.
Nieman, L.K., and Ilias, I. (2005). Am. J. Med. 118, 1340–1346.
Petrovic, N., Walden, T.B., Shabalina, I.G., Timmons, J.A., Cannon, B., and
Nedergaard, J. (2010). J. Biol. Chem. 285, 7153–7164.
Rodriguez-Cuenca, S., Monjo, M., Gianotti, M., Proenza, A.M., and Roca, P.
(2007). Am. J. Physiol. 292, E340–E346.
Saito, M., Okamatsu-Ogura, Y., Matsushita, M., Watanabe, K., Yoneshiro, T.,
Nio-Kobayashi, J., Iwanaga, T., Miyagawa, M., Kameya, T., Nakada, K., et al.
(2009). Diabetes 58, 1526–1531.
Sell, H., Berger, J.P., Samson, P., Castriota, G., Lalonde, J., Deshaies, Y., and
Richard, D. (2004). Endocrinology 145, 3925–3934.
Soumano, K., Desbiens, S., Rabelo, R., Bakopanos, E., Camirand, A., and
Silva, J.E. (2000). Mol. Cell. Endocrinol. 165, 7–15.
van Marken Lichtenbelt, W.D., Vanhommerig, J.W., Smulders, N.M., Dros-
saerts, J.M., Kemerink, G.J., Bouvy, N.D., Schrauwen, P., and Teule, G.J.
(2009). N. Engl. J. Med. 360, 1500–1508.
Virtanen, K.A., Lidell, M.E., Orava, J., Heglind, M., Westergren, R., Niemi, T.,
Taittonen, M., Laine, J., Savisto, N.J., Enerba¨ck, S., and Nuutila, P. (2009).
N. Engl. J. Med. 360, 1518–1525.
Yanase, T., Fan, W., Kyoya, K., Min, L., Takayanagi, R., Kato, S., and Nawata,
H. (2008). J. Steroid Biochem. Mol. Biol. 109, 254–257.
Zingaretti, M.C., Crosta, F., Vitali, A., Guerrieri, M., Frontini, A., Cannon, B.,
Nedergaard, J., and Cinti, S. (2009). FASEB J. 23, 3113–3120.
